Investment in India's Symbiotec shows firm demand for niche plays
This article was originally published in Scrip
Executive Summary
Private equity firm Actis's $48m investment in the leading Indian corticosteroids active pharmaceutical ingredients manufacturer Symbiotec Pharmalab is indicative of firm active interest in niche verticals in India, amid speculation of more such deals on the horizon.